Showing results (91-100 of 133) with videos related to
Sort By:
Pageof 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2021
Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch SyndromeChristopher J Schwartz, Edaise M da Silva, Antonio Marra, et al.Oncogene|February 11, 2022
Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progressionAlba Mota, Sara S Oltra, Pier Selenica, et al.Journal of the National Cancer Institute|July 9, 2021
Paired Tumor-Normal Sequencing Provides Insights Into the TP53-Related Cancer Spectrum in Patients With Li-Fraumeni SyndromeOzge Ceyhan-Birsoy, Pier Selenica, M Herman Chui, et al.Histopathology|December 31, 2019
Immunohistochemical assessment of HRAS Q61R mutations in breast adenomyoepitheliomasFresia Pareja, Michael S Toss, Felipe C Geyer, et al.NPJ Breast Cancer|July 13, 2023
Clinicopathologic and genomic features of lobular like invasive mammary carcinoma: is it a distinct entity?Jing Yu, Edaise M da Silva, Hae-Sun La, et al.Proceedings of the National Academy of Sciences of the United States of America|December 13, 2019
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancerXiaoyong Fu, Resel Pereira, Carmine De Angelis, et al.Nature Cancer|June 28, 2022
Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancerKevin M Boehm, Emily A Aherne, Lora Ellenson, et al.Biorxiv : the Preprint Server for Biology|May 15, 2024
APOBEC3 mutagenesis drives therapy resistance in breast cancerAvantika Gupta, Andrea Gazzo, Pier Selenica, et al.Journal of the National Cancer Institute|March 6, 2018
The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation CarriersBritta Weigelt, Rui Bi, Rahul Kumar, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2026
A Phase II Trial of Olaparib Plus Pembrolizumab in Patients with Recurrent Copy-Number High/p53-Abnormal Endometrial CancerMaria M Rubinstein, Jennifer Y Ge, Qin Zhou, et al.Pageof 14